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Aims The low lymphocyte counts and high neutrophil leucocyte fractions have been associated with poor prognosis
in chronic heart failure. We hypothesized that the baseline ratio of the neutrophil leucocytes to the lymphocytes
(NL ratio) would predict the outcome of chronic heart failure patients undergoing cardiac resynchronization
therapy (CRT).
Methods
and results
The qualitative blood counts and the serum levels of N-terminal of the prohormone brain natriuretic peptide
(NT-proBNP) of 122 chronic heart failure patients and 122 healthy controls were analysed prospectively in this obser-
vational study. The 2-year mortality was considered as primary endpoint and the 6-month reverse remodelling (≥15%
decrease in the end-systolic volume) as secondary endpoint. Multivariable regression analyses were applied and net
reclassification improvement (NRI) and integrated discrimination improvement (IDI) were calculated. The NL ratio
was elevated in chronic heart failure patients when compared with the healthy controls [2.93 (2.12–4.05) vs. 2.21
(1.64–2.81), P, 0.0001]. The baseline NL ratio exceeding 2.95 predicted the lack of the 6-month reverse remodelling
[n ¼ 63, odds ratio ¼ 0.38 (0.17–0.85), P ¼ 0.01; NRI ¼ 0.49 (0.14–0.83), P ¼ 0.005; IDI ¼ 0.04 (0.00–0.07), P ¼ 0.02]
and the 2-year mortality [n ¼ 29, hazard ratio ¼ 2.44 (1.04–5.71), P ¼ 0.03; NRI ¼ 0.63 (0.24–1.01), P ¼ 0.001;
IDI ¼ 0.04 (0.00–0.08), P ¼ 0.02] independently of the NT-proBNP levels or other factors.
Conclusion The NLratio is elevated in chronicheart failure andpredictsoutcome afterCRT. According to the reclassificationanalysis,
4% of the patients would have been better categorized in the prediction models by combining the NT-proBNP with the
NL ratio. Thus, a single blood count measurement could facilitate the optimal patient selection for the CRT.
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Introduction
The white blood cells (WBCs) or leucocytes are the effectors
and coordinators of the chronic cellular inflammatory process
in which several WBC subgroups are involved, such as the
lymphocytes, monocytes, neutrophils, basophils, and the eosino-
phils.1 The leucocytosis refers to an increase in the number of the
WBC and this phenomenon predicts an increased mortality and
hospitalization rate in patients with chronic heart failure.2 The
relative decrease of the lymphocytes, termed as lymphocytope-
nia, has also been associated with disease progression and poor
outcome.3 Similarly, the increase in the number of the neutro-
phils (neutrophilia) predicts death and hospitalization in chronic
heart failure.4
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The cardiac resynchronization therapy (CRT) is highly effective
treatment for the medically refractory chronic heart failure patients
with intra- and interventricular conduction delay by biventricular
pacing.5,6 Most of the patients respond adequately to the therapy
with improvement of the functional status and the reverse remodel-
ling of the failing heart. This latter can be objectively quantified by
imaging modalities and based on those several response criteria
had been established to assess the success of the therapy.7,8
The N-terminal of the prohormone brain natriuretic peptide
(NT-proBNP) is a widely used traditional biomarker in the diagnosis
establishment, the treatment guidance and the prognosis prediction
in chronic heart failure. The lower levels of the NT-proBNP predict
the long-term survival of the patients and also the short-term
6-month response to the CRT.9
It is widely accepted that the chronic heart failure is associated with
an ongoing inflammatory response, however, the exact mechanism is
not fully described.1 We hypothesized that the ratio of the neutrophil
leucocytes to the lymphocytes (NL ratio) is elevated and would
predict the 6-month reverse remodelling and the 2-year mortality
of the patients independently of the baseline NT-proBNP levels or
other factors. We aimed to test the potential clinical utility of our
models with reclassification methods.
Methods
Study population and study design
The purpose of this prospective single-centre observational follow-up
study was to evaluate the prognostic impact of routine laboratory para-
meters on the clinical outcome of chronicheart failurepatientswith CRT.
The physiciansparticipating in the study were aware of the blood count of
the patients as this is part of the basic laboratory tests before CRT,
however, no further calculations were performed (e.g. the NL ratio).
A total of 131 consecutive patients with medically refractory heart
failure referred to our Heart and Vascular Center between September
2009 and December 2010 for CRT implantation, according to the
current guidelines.10 The inclusion criteria included previously diagnosed
and medically treated chronic heart failure [New York Heart Association
(NYHA) class II– IV] with wide QRS in electrocardiogram (ECG)
(.120 ms) and a severely reduced (,35%) left ventricular ejection
fraction (LVEF). We considered autoimmune diseases, haematologic
diseases, acute or chronic inflammatory diseases, and malignancies as
exclusion criteria, and three patients were excluded on this basis. The
procedure of the CRT implantation was performed by implantation of
a left ventricular lead into the sidebranch of the coronary sinus, a
right ventricular lead in a septal position and a right atrial lead where
appropriate.
We followed up the patients for 2 years and routine laboratory tests,
clinical examinations, ECG, and echocardiographic measurements were
carried out. The clinical examinations included heart failure functional as-
sessment with NYHA classification. Echocardiographic measurements
were performed using Philips iE33 system to calculate the LVEF with
Simpson’s biplane method and the left ventricle volumes using Teicholz
method.
In the final analysis, 122 chronic heart failure patients were included
with complete laboratory and clinical data. The data of 122 age, gender,
and BMI matched healthy control subjects were also analysed who parti-
cipated in the voluntary ‘Budakala´sz Study’ of our clinic.11 We considered
the all-cause 2-year mortality of the chronic heart failure patients as the
primary endpoint. The secondary endpoint was the 6-month reverse re-
modelling [defined as at least 15% absolute decrease in the end-systolic
volume (ESV)].7
Prior to the enrolment all patients provided written informed consent.
The local Ethics Committee of the Semmelweis University had approved
the protocol which was in accordance with the Helsinki Declaration.
Laboratory measurements
Wecollected serum and ethylenediaminetetraacetic acid plasma samples
for biochemical measurements at baseline and 6 months after CRT im-
plantation. The qualitative blood counts were measured on the day of
blood sampling as the part of the routine clinical evaluation. Aliquots
for the NT-proBNP were processed within 2 h of sampling and were
stored frozen at2808C until the later measurements. Blood cell count-
ing was performed by using the Symex XS-1000i (Kobe, Japan) system
with fluorescent flow cytometry technology. The absolute numbers of
the WBC subgroups were automatically calculated by the analyser
then displayed their relative percentages to the total WBC counts. The
levels of the NT-proBNP were measured with electrochemilumines-
cence technology by Cobas e 411 analyser (Mannheim, Germany)
using Roche Elecsys NT-proBNP II kits (Cat. No.: 04842464190, Mann-
heim, Germany).
Statistical analysis
The parameters reported in this study differed from the normal distribu-
tions, thus we used non-parametric tests, and the data are expressed as
median values with interquartile ranges (25–75%) and as percentages
with event numbers. A two-tailed P-value of,0.05 was considered stat-
istically significant in all cases.
For comparison we applied the Mann–Whitney, the Wilcoxon
matched-pairs signed rank and thex2 tests, as appropriate. The optimum
cut-off values were established by using the receiver operating character-
istic (ROC) analysis.
The reference models of the reverse remodelling and the survival pre-
diction included the statistically significant variables of the univariate lo-
gistic and Cox regression analysis. The NT-proBNP, then the leucocyte
parameters were entered into the reference models in a forward
What’s New?
† It has been shown previously that the baseline ratio of the
neutrophil leucocytes to the lymphocytes (NL ratio) predicts
the 6-month reverse remodelling following cardiac resynchro-
nization therapy (CRT).
† Our analysis has revealed that the NL ratio is elevated in
chronic heart failure and predicts not only the reverse remod-
elling, but also the 2-year mortality rate of the patients with
CRT, independently of the N-terminal of the prohormone
brainnatriuretic peptide (NT-proBNP) levels orother factors.
† Patients with an NL ratio higher than 2.95 before the CRT im-
plantation experience up to three times higher risk not going
under reverse remodelling or to pass away before the 2-year
post-implantation period.
† The combined use of the NT-proBNP with the NL ratio
improves the risk stratification, 4% of the patients would
have been better categorized with a simple blood count
measurement.
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stepwise way. The continuous variables were dichotomized based on
their best fitting cut-off values.
We aimed to present the exact clinical benefit of the leucocyte para-
meters in the prediction models, thus we validated and calibrated these
models by the Hosmer–Lemeshow test and showed the overall model
performance improvement by the changes of the Brier score and the
Nagelkerke’s R2. Reclassification and discrimination procedures were
performed including the c-statistic with DeLong test, the net reclassifica-
tion improvement (NRI) and the integrated discrimination improvement
(IDI) in order to numerically reveal those patients who profit with the
new marker.12
The reported statistical analysis was carried out by using IBM SPSS
22 (Apache Software Foundation, USA), Graphpad Prism 6.03 (Graph-
Pad Softwares Inc., USA), PASS 2008 (NCSS, USA), and the open
source R software (R version 3.1.2 with PredictABEL and pROC
packages).
Results
The baseline characteristics of the study
population
The median age of the patients was 67 years, 82% of them were male,
59% hadaheart failureof ischaemicorigin, 81%had left bundlebranch
block (LBBB) in the ECG and the median QRS width was 163 ms. The
median LVEF was 27% and the functional status showed that 85% of
the patients were in NYHA class III or IV (Table 1).
The NL ratio was elevated in chronic heart failure patients when
compared with the healthy controls [2.93 (2.12–4.05) vs. 2.21
(1.64–2.81), P, 0.0001] without significant difference in the total
leucocyte counts [6.9 (5.8–8.1) vs. 6.8 (5.8–8.1) × 103 mL– 1, P ¼
0.81, respectively] (Supplementary material online, Table S1).
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Table 1 Baseline parameters as predictors of the 6-month reverse remodelling and the 2-year mortality
Heart failure patients (n5 122) Six-month reverse remodelling Two-year all-cause mortality
OR 95% CI of OR x2 P-Value HR 95% CI of HR x2 P-Value
Clinical variables
Age (years) 67 (61–73) 0.67 0.45–0.80 3.93 0.03 0.96 0.67–1.37 0.03 0.84
Male gender 101 (82) 0.36 0.13–0.99 3.77 0.04 1.35 0.47–3.89 0.31 0.57
BMI (kg/m2) 27 (25–29) 1.27 0.88–1.83 1.63 0.20 0.87 0.60–1.27 0.48 0.48
Ischaemic 72 (59) 0.85 0.41–1.75 0.18 0.66 2.04 1.04–4.43 3.81 0.04
LBBB 100 (81) 1.69 0.66–4.32 1.22 0.26 0.42 0.19–0.93 4.54 0.03
CRT-D 20 (16) 2.52 0.89–7.08 3.09 0.07 0.53 0.16–1.71 1.06 0.30
QRS (ms) 163 (139–184) 1.57 1.02–2.48 3.83 0.04 1.03 0.72–1.48 0.03 0.85
LVEF (%) 27 (23–33) 0.90 0.63–1.30 0.27 0.60 0.93 0.64–1.35 0.12 0.72
ESV (mL) 210 (147–246) 1.51 1.02–2.24 4.33 0.03 0.99 0.68–1.45 0.00 0.99
EDV (mL) 303 (242–351) 1.56 1.05–2.31 5.01 0.02 1.02 0.71–1.49 0.02 0.88
NYHA III,IV 104 (85) 0.25 0.07–0.82 5.20 0.02 2.57 0.61–10.81 1.65 0.19
Hypertension 65 (53) 0.92 0.45–1.89 0.04 0.83 1.28 0.61–2.69 0.45 0.50
Hyperlipidaemia 27 (22) 0.46 0.19–1.12 2.89 0.08 0.53 0.18–1.53 1.35 0.24
Diabetes m. 47 (38) 0.83 0.40–1.74 0.22 0.63 2.82 1.33–5.99 7.37 0.007
ACEi/ARB 110 (90) 1.07 0.20–5.53 0.00 0.93 0.63 0.15–2.69 0.37 0.54
BB 116 (95) 2.31 0.65–8.13 1.71 0.19 0.21 0.09–0.48 13.67 ,0.0001
MRI 86 (70) 1.76 0.80–3.88 2.01 0.15 0.63 0.19–1.34 1.41 0.23
Laboratory data
NT-proBNP (pg/mL) 2626 (1515–5101) 0.59 0.38–0.92 5.36 0.02 1.39 1.08–1.80 6.56 0.01
NL ratio 2.93 (2.12–4.05) 0.67 0.46–0.99 3.88 0.04 1.48 1.13–1.94 8.11 0.004
Neutrophils (%) 66.2 (60.0–72.9) 0.66 0.45–0.97 4.45 0.03 1.70 1.14–2.53 6.80 0.009
Lymphocytes (%) 22.9 (17.6–28.2) 1.65 1.12–2.43 6.46 0.01 0.52 0.34–0.79 9.54 0.002
Monocytes (%) 6.7 (5.4–8.4) 0.73 0.51–1.07 2.49 0.11 1.15 0.81–1.62 0.64 0.42
Eosinophils (%) 2.2 (1.4–3.0) 1.02 0.71–1.46 0.02 0.88 1.13 0.83–1.55 0.64 0.42
Basophils (%) 0.5 (0.3–0.8) 1.19 0.82–1.73 0.91 0.33 0.60 0.36–1.00 3.75 0.05
WBC (×103 mL–1) 6.9 (5.8–8.1) 0.85 0.59–1.24 0.65 0.42 1.53 1.20–1.95 9.21 0.003
Data are expressed as median with interquartile range for continuous variables and as event numbers with percentage for categorical variables. The 6-month reverse remodelling
(n ¼ 63, ≥15% decrease in the ESV) was tested by using the univariate logistic regression analysis and the 2-year mortality (n ¼ 29) was assessed by using the univariate Cox
regression analysis. The continuous variables were standardized by 1 SD increase. The odds and hazard ratios refer for the presence vs. absence in case of categorical variables
and 1 SD increase in case of continuous variables.
OR, odds ratio; HR, hazard ratio; CI, confidence interval;x2, Chi squared; BMI, body mass index; Ischaemic, ischaemic aetiology of the heart failure; LBBB, left bundle branch block;
CRT-D, cardiac resynchronization therapy with implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; ESV, end-systolic volume; EDV, left ventricular
end-diastolic volume; NYHA III,IV, New York Heart Association classification III,IV; ACEi/ARB, angiotensin convertase inhibitor/angiotensin receptor blocker; BB, beta blocker;
MRI, mineralocorticoid receptor inhibitor; NT-proBNP, N-terminal of the prohormone brain natriuretic peptide.
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Changes in echocardiographic and
laboratory parameters 6 months after
cardiac resynchronization therapy
implantation
The CRT has led to a statistically significant increases in the LVEF
[27 (23–33) vs. 37 (30–40)%, P, 0.0001] and decreases in the
left ventricular end-systolic volume [210 (150–276) vs. 167 (114–
238) mL, P, 0.0001] and the left ventricular end-diastolic volume
[303 (242–361) vs. 259 (210–326) mL, P, 0.0001] in the cohort.
We have observed statistically significant decreases in the NL
ratio [2.93 (2.12–4.05) vs. 2.82 (2.05–3.05), P ¼ 0.04] and the
NT-proBNP levels [2626 (1515–5101) vs. 1688 (757–3554)
pg/mL, P ¼ 0.001] 6 months after implantation.
The baseline ratio of the neutrophil
leucocytes to the lymphocytes in the
prediction of the 6-month reverse
remodelling
From the aspect of the echocardiographic reverse remodelling fol-
lowing the CRT, 63 patients (52%) were categorized as responders
and 59 patients (48%) as non-responders.
Responders at baseline had lower NL ratio [2.62 (1.90–3.71) vs.
3.12 (2.35–4.66), P ¼ 0.01] and lower NT-proBNP levels [2315
(1004–3989) vs. 3305 (1869–6019) pg/mL, P ¼ 0.004, respective-
ly]. Using the ROC analysis, we defined the NL ratio 2.95 [area
under the curve (AUC) ¼ 0.63 (0.53–0.73)] and the NT-proBNP
1522 pg/mL [AUC ¼ 0.64 (0.55–0.74)] as optimal cut-off values
for the prediction models and their diagnostic accuracy is shown in
Table 2.
The univariate logistic regression analysis revealed that the reverse
remodelling following the CRT was significantly associated with
younger age, female gender, wider QRS, and better NYHA functional
status at baseline, thus these variables composed of the later multi-
variable reference model (Table 1).
We entered the NT-proBNP to the reference model, then the NL
ratio in a forward stepwise way and the baseline NL ratio exceeding
2.95 independently predicted the lack of the 6-month reverse re-
modelling [odds ratio ¼ 0.38 (0.17–0.85), P ¼ 0.01], as shown in
Table 3.
The baseline ratio of the neutrophil
leucocytes to the lymphocytes in the
prediction of the 2-year mortality
Up to a median follow-up period of 787 days, 29 (23%) patients died.
Those who survived the follow-up period had lower baseline NL
ratio [2.70 (2.05–3.68) vs. 3.90 (2.87–5.65), P ¼ 0.001] and lower
NT-proBNP levels [2418 (1116–4050) vs. 4959 (2429–6864)
pg/mL, P ¼ 0.002]. The ROC analysis showed that the predefined
NL ratio of 2.95 [AUC ¼ 0.69 (0.58–0.80)] and the NT-proBNP
level of 1522 pg/mL [AUC ¼ 0.70 (0.60–0.80)] were also optimal
for the mortality prediction models (Table 2). The Kaplan–Meier sur-
vival curves based on the NL ratio are shown in Figure 1.
The 2-year survival of the patients in the univariate Cox regression
analysis was significantly predicted by the LBBB pattern of the ECG,
the use of beta-blocker therapy, the absence of diabetes mellitus, and
the non-ischaemic aetiology of the heart failure, and consequently
these parameters comprising the reference model of the multivari-
able analysis (Table 1).
Using the multivariable Cox regression analysis, we have adjusted
the NT-proBNP to the reference model, then the NL ratio in a
forward stepwisewayand the NL ratio exceeding 2.95 independently
predicted the 2-year mortality of the patients [hazard ratio ¼ 2.44
(1.04–5.71), P ¼ 0.03], as shown in Table 3.
Testing of the prediction models
The regression analyses with a sample size of the 122 patients
achieved a power .90% to detect the presented odds and hazard
ratios. Building each step of the prediction models achieved statistic-
ally significant changes in the Chi scores, thus our models were con-
sidered valid (Table 4). The Hosmer–Lemeshow test assesses if the
observed event rates match the expected event rates in the predic-
tion steps, and since the test’s P values did not differ statistically signifi-
cant throughout the analysis, the occurred event rates were similar to
the expected event rates, in other words the models were calibrated
well. The overall performance of the prediction models improved by
adding the NL ratio to the reference models because the Nagelk-
erke’s R2 value has increased (which indicates how well the data fit
in the model), while the Brier score has decreased (which measures
the probability of accidental events in the predictions) in each step, as
shown in Table 4.
The discriminative power tested by means of the c-statistic
demonstrated that the NL ratio has increased the AUC of the predic-
tion (reverse remodelling from 0.66 to 0.71 and mortality from 0.77
to 0.79). We also displayed how the discrimination slope becomes
steeper (the reverse remodelling from 0.11 to 0.19 and the mortality
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Table 2 Diagnostic accuracy of the biomarkers in the
prediction models
Test Six-month
reverse
remodelling
Two-year
all-cause
mortality
No Yes Yes No
NL ratio ≥2.95 36 23 21 38
NL ratio ,2.95 23 40 8 55
Sensitivity 61 (47–73) 72 (53–87)
Specificity 63 (50–75) 59 (48–69)
Positive predictive value 61 (47–73) 36 (24–49)
Negative predictive value 63 (50–75) 87 (77–94)
NT-proBNP ≥1522 pg/mL 51 41 27 65
NT-proBNP,1522 pg/mL 8 22 2 22
Sensitivity 86 (75–94) 93 (77–99)
Specificity 35 (23–48) 30 (21–41)
Positive predictive value 55 (45–66) 29 (20–40)
Negative predictive value 73 (54–88) 93 (78–99)
The values are given as case numbers for the tests. Sensitivity, specificity, positive,
and negative predictive values are expressed as percentage with 95% confidence
interval.
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from 0.22 to 0.27) by adding the NL ratio to the models (box plots
in Figures 2 and 3).
We have observed a significant improvement in the NRI [NRI
reverse remodelling: 0.49 (0.14–0.83), P ¼ 0.005 and mortality:
0.63 (0.24–1.01), P ¼ 0.001] and also a significant improvement in
the IDI [IDI reverse remodelling: 0.04 (0.00–0.07),P ¼ 0.02 andmor-
tality 0.04 (0.00–0.08), P ¼ 0.02] by combining the models with the
NL ratio (Table 4).
The IDI ¼ 0.04 value for the reverse remodelling and also for
the mortality demonstrates that 4% of the patients were better cate-
gorized in these prediction models by adding the NL ratio to the
NT-proBNP adjusted reference models. Thus, 5 patients of the 122
cases had lower baseline NT-proBNP levels than 1522 pg/mL and
still did not experience reverse remodelling, or died 2 years later.
On the other hand, all of these patients had an elevated NL ratio.
Discussion
Synopsis of key findings
We have found that the baseline NL ratio is elevated in chronic
heart failure and the NL ratio predicts the 6-month reverse
remodelling and the 2-year mortality of the patients undergo-
ing CRT independently of the NT-proBNP levels or other
factors.
Patients with an NL ratio higher than 2.95 before the CRT implant-
ation experience up to three times higher risk not going under
reverse remodelling or to pass away in the post-implantation
period. According to the reclassification analysis, the combined use
of the NT-proBNP with the NL ratio improves the risk stratification:
5 patients of the 122 cases were better categorized with a simple
blood count measurement.
Possible mechanisms and explanations
The lymphocytes (T cells, B cells, and NK cells) are the effectors of the
adaptive and the innate immune system.1 The lymphocytopenia is
common finding among chronic heart failure patients associated with
adverse outcome.3 The neurohormonal activation, oxidative stress, and
the chronic inflammation in heart failure increase the catecholamine
release13 and the plasma cortisol levels14 leading to bone marrow sup-
pression and down-regulation of the lymphocyte proliferation and differ-
entiation14 with aggravated lymphocyte apoptosis.15
The natriuretic peptides such as the NT-proBNP are up-regulated
in heart failure in order to compensate the disease progression by
natriuresis, vasodilation, and the suppression of the sympathetic
nervous activation.16 Experimental data suggest that the natriuretic
peptides exert a significant impact on the WBCs: the atrial natriuretic
peptide inhibits the expression of adhesion molecules and reduce the
production of various lymphocyte subgroups,17 while the BNP over-
expression after acute myocardial infarction facilitates the neutrophil
infiltration in rat model.18
The neutrophils release reactive oxygen species, activate phago-
cytosis, and pro-inflammatory agents such as the C-reactive protein,
tumour necrosis factor-alpha, interleukin-6, and trigger myocardial
injury.1 On the other hand, the interleukin-6 directly promotes the
neutrophil release to the circulation from the bone marrow.19
These inflammatory mediators are commonly elevated in chronic
heart failure patients which could lead to the neutrophilia.20
The role of the NL ratio in the CRT has been recently investigated
by Agacdiken et al.,21 who included 70 patients in their study and
demonstrated that the echocardiographic response to the CRT
was associated with lower baseline NL ratio. Our results confirm
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Figure 1 Influence of the baseline NL ratio on the 2-year all-
cause mortality of the patients. We compared the Kaplan–Meier
survival curves using log-rank test.
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Table 3 The role of the leucocyte parameters in the prediction of the study outcomes
Six-month reverse remodelling P-Value Two-year all-cause mortality P-Value
OR 95% CI of OR x2 HR 95% CI of HR x2
NL ratio ≥2.95 0.38 0.17–0.85 5.54 0.01 2.44 1.04–5.71 4.24 0.03
Neutrophils ≥63.6% 0.37 0.15–0.88 5.06 0.02 2.41 1.06–5.46 4.49 0.03
Lymphocytes ≤22% 0.41 0.18–0.90 4.88 0.02 2.42 0.91–6.41 3.19 0.07
The 6-month reverse remodelling (n ¼ 63) was defined as at least 15% decrease in the ESV. The reference multivariable logistic regression analysis included male gender, NYHA class
III/IV, age ≥70 years, and QRS ≥160 ms. In a forward stepwise way, we adjusted the NT-proBNP ≥1522 pg/mL to the reference model, then the leucocyte parameters separately.
The 2-year mortality (n ¼ 29) was assessed by using multivariable Cox regression. The reference model included ischaemic heart failure aetiology, beta-blocker therapy, LBBB,
and diabetes mellitus. We adjusted the NT-proBNP and the leucocyte parameters as described in the logistic regression. The odds ratios (ORs) and the hazard ratios (HRs) refer for
the presence or absence of the outcome.
CI, confidence interval; x2, Wald Chi square; NT-proBNP, N-terminal of the prohormone brain natriuretic peptide; NL ratio, ratio of the neutrophil leucocytes and the lymphocytes.
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Table 4 Testing of the prediction models
Six-month reverse remodelling Two-year all-cause mortality
Reference model Reference model
1NT-proBNP
Reference model
1NT-proBNP
1NL ratio
Reference model Reference model
1NT-proBNP
Reference model
1NT-proBNP
1NL ratio
Validation
Overall x2 12.00 16.09 21.75 25.83 29.48 36.01
P (overall) 0.01 0.007 0.01 ,0.0001 ,0.0001 ,0.0001
Calibration
HL test x2 2.90 10.88 7.93 1.27 4.89 4.60
P (HL test) 0.94 0.20 0.44 0.99 0.76 0.79
Performance
Nagelkerke’s R2 0.12 0.16 0.21 0.24 0.29 0.34
Brier score 0.22 0.21 0.20 0.14 0.13 0.12
Reclassification
c-Statistic 0.65 (0.56–0.75) 0.66 (0.56–0.76) 0.71 (0.62–0.80) 0.74 (0.63–0.85) 0.77 (0.67–0.87) 0.79 (0.69–0.89)
P (c-statistic) 0.85 0.13 0.29 0.40
NRI (95% CI) 0.42 (0.13–0.72) 0.49 (0.14–0.83) 0.46 (0.20–0.72) 0.63 (0.24–1.01)
P (NRI) 0.004 0.005 0.0005 0.001
IDI (95% CI) 0.02 (0.00–0.05) 0.04 (0.00–0.07) 0.03 (0.00–0.06) 0.04 (0.00–0.08)
P (IDI) 0.05 0.02 0.01 0.02
The 6-month reverse remodelling (n ¼ 63) was defined as at least 15% decrease in the ESV. The referencemodel for the logistic regression analysis included male gender, NYHA class III/IV, age≥70years, andQRS≥160 ms. The reference model for
the 2-year mortality (n ¼ 29) using Cox regression analysis included ischaemic heart failure aetiology, beta-blocker therapy, LBBB, and diabetes mellitus. In a forward stepwise way, we adjusted the NT-proBNP ≥1522 pg/mL to the reference
models, then the NT ratio ≥2.95.
x2, Chi square; HL test, Hosmer–Lemeshow test; 95% CI, 95% confidence interval; NRI, net reclassification improvement; IDI, integrated discrimination improvement; NT-proBNP, N-terminal of the prohormone brain natriuretic peptide; NL ratio,
ratio of the neutrophil leucocytes and the lymphocytes.
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and expand those preliminary findings, as we were the first to reveal
the value of the NL ratio in the mortality prediction as well.
The CRT is one of the most important advances in the therapy of
the severe chronic heart failure in the past decade. However, even
with our increasing knowledge on the therapy, the rate of the
non-responders is still high. Thus, the need for the appropriate
patient selection in the CRT is outmost important. With analysing
the landmark trials several predictors had been identified, such as
age, gender, heart failure aetiology, LBBB or the QRS width, and
implemented in the guidelines.10 Besides their success, the need for
identifying different predictors that characterize different aspects of
the heart failure, for instance the inflammatory markers is still there.
On the other hand, the prediction studies commonly leave out the
comparison of the new marker to standard risk markers and the dis-
crimination analysis itself, which could actually prove that the patients
do really have higher risk with the new marker than without the new
marker.22 The gold standard for the discrimination processes used to
be the c-statistic, but novel studies showed its lack in sensitivity,23 thus
new methods have been developed, such as the NRI and IDI.12 Their
positive value showsan improvement in the discriminationsquality. In
our analysis, both NRI and IDI were positive, so the combined use of
the NL ratio with the traditional heart failure biomarker, the
NT-proBNP improved the risk prediction.
Strengths and limitations
Modern, automated qualitative blood count systems can easily deter-
mine the fractions of the lymphocytes and the neutrophils with great
precision and most importantly with low cost. The main strength of
our study is that all patients have blood count data in the clinical prac-
tice, thus with a little effort the NL ratio could be calculated (or at
least estimated) and an elevated NL ratio should draw attention to
a possible adverse outcome.
Since the reference models included the most important prognos-
tic factors (age, gender, LBBB, aetiology, and QRS width) and were
adjusted to the traditional predictive marker, the NT-proBNP, the
results are therefore independent of their influence.
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Figure3 Improvement in the risk prediction of the 2-year all-cause mortality using the baseline NL ratio. The discrimination slopes are calculated
as the difference between the mean predicted probabilities, thus the difference between the slopes is the integrated discrimination index itself. The
differences of the receiver operating curves (c-statistic) are demonstrated on the right side.
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Although we numerically determined the advantage of the NL
ratio with appropriate power, clinical application could be recom-
mended only after establishment its usefulness in larger population
of heart failure patients with CRT. The low patient and event
numbers in this study resulted in low sensitivity and specificity
values for the NL ratio, but an acceptable negative predictive value
was achieved, indicating its possible role in identifying low-risk
patients. In this line, our results should be considered only as prelim-
inaryand hypothesis-generating. Furtherprospective trials areclearly
needed to test this promising new biomarker.
Conclusions
The NL ratio was found to predict the 6-month reverse remodelling
and the 2-year mortality in the CRT of chronic heart failure. A single
blood count measurement could facilitate the optimal patient selec-
tion for the CRT independently of traditional biomarkers or other
factors.
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Supplementary material is available at Europace online.
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